It comes days after the drugmaker announced that its vaccine appears 95% effective at preventing mild to severe COVID-19 disease in a large, ongoing study.
White House spokesman Brian Morgenstern did not address whether Biden's team would be briefed, saying vaccine distribution plans from the U.S. Centers for Disease Control and Prevention and state governors were publicly available.
A final analysis of the Phase 3 trial of Pfizer's coronavirus vaccine shows it was 95 per cent effective in preventing infections.
Pfizer's vaccine candidate was shown to be more than 90% effective in preventing COVID-19 based on initial data, but the company faces distribution and storage challenges.
Trump's defiant remarks comes amid a record breaking surge in new COVID-19 cases in the United States.
Pfizer said Monday that early results from the vaccine suggests the shots may be a surprisingly robust 90 per cent effective at preventing COVID-19.
BioNTech, first in the race to produce evidence of a working COVID-19 vaccine, is planning to price the two-shot regimen below "typical market rates."
Although Pfizer's coronavirus vaccine data looks promising, experts say we should remain 'cautious' as the full data has still not been released.
Pfizer cautioned the initial protection rate might change by the time the study ends. Even revealing such early data is highly unusual.
Pfizer said on Friday it may file for authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November.
The trial, which is being conducted in four countries including the United States, has enrolled more than 37,000 participants.